{"prompt": "['12.0 Bibliography', '1]', 'Machiels JP et al: Afatinib versus methotrexate as second-line treatment in patients with', 'recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after', 'platinum-based therapy (LUX-Head & Neck 1): an open label, randomised phase 3 trial. Lancet', 'Oncol 2015; 16:583-94.', '2]', 'https://www.necn.org/professionals/physician_ gls/PDF/head-and-neck.pdf', '3]', 'Ferris RL, et al .Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and', 'Neck.N Engl J Med. 2016 Nov 10;375(19):1856-1867.', '4]', 'Seiwert TY, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or', 'metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label,', 'multicentre, phase 1b trial. Lancet Oncol. 2016 Jul; 17(7):956-65.', '5)', 'Keir ME et al: PD-1 and its ligands in tolerance and immunity. An. Rev Immunol. 2008.', '26:677-704', '6', 'Itlekofer AM et al: At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as', 'cancer immunotherapy, J. Leukocyte Biol 2013;94:25-39', '7', 'Francisco LM et al: PD-LI regulates the development, maintenance, and function of', 'induced regulatory T cells. J. Exp. Med. 2009;206:3015-3029', '8', 'Marabelle A et al: Depleting tumor-specific Tregs at a single site eradicates disseminated', 'tumors J Clin Invest 2013;123:2447-6', '9', 'Ladoire S et al: Pathologic Complete response to neoadjuvant chemotherapy of breast', 'carcinoma is associated with the disappearance of tumor-infiltrating Foxp3+ regulatory cells. Clin', 'Cancer Res 2008;14:2413-2420', '10', 'Li X et al: Efficient Treg depletion induces T-cell infiltration and rejection of large tumors.', 'Eur. J. Immunol. 2010;40:3325-3335', 'CONFRONT Study v. 1.1 del 07/05/2018 - Study Protocol', '48']['11', 'Liu K, Tan S, Chai Y, Chen D, Song H, Zhang CW, Shi Y, Liu J, Tan W, Lyu J, Gao S, Yan J,', 'Qi J, Gao GF. Structural basis of anti-PD-LI monoclonal antibody avelumab for tumor therapy.', 'Cell Res. 2017 Jun;27(1):151-153.', '12', 'Ghiringhelli F et al: Metronomic cyclophosphamide regimen selectively depletes', 'CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer', 'patients. Cancer Immunol Immunother 2007;56:641-648', '13', 'Kroemer G et al: Immunogenic cell death in cancer therapy. Annu. Rev. Immunol.', '2013;31:51-72', '14 Adkins I et al: Physical modalities inducing immunogenic tumor cell death for cancer', 'therapy. Oncoimmunology 3:12, e968434;2014', '15', 'Harvey RD, Morgan ET. Cancer, inflammation, and therapy: effects on cytochrome p450-', 'mediated drug metabolism and implications for novel immunotherapeutic agents. Clin Pharmacol', 'Ther. 2014 Oct;96(4):449-57.', '16', 'Herbst RS et al. Predictive correlates of response to the anti-PD-LI antibody MPDL3280A', 'in cancer patients Nature. 2014 Nov 27;515(7528):563-7.', '17] Heery C.R. et al: Avelumab for metastatic or locally advanced previously treated solid', 'tumours (Javelin solid tumor): a phase la, multicohort, dose-escalation trial. Lancet Oncol', '2017;18:587-598', '18] Penel N et al: Cyclophosphamide-based metronomic chemotherapy: after 10 years of', 'experience, where do we stand and where are we going? Critical Rev Oncol/hematol 2012;82:40-', '50', '19] Hao Y-B et al, New insights into metronomic chemotherapy-induced immunoregulation.', 'Cancer Letters 2014;354:220-226', '20] Penel N et al: Megestrol acetate versus metronomic cyclophosphamide in patients having', 'exhausted all effective therapies under standard care. Br J Cancer', '2010;102:1207-12', 'CONFRONT Study V. 1.1 del 07/05/2018 - Study Protocol', '49']\n\n###\n\n", "completion": "END"}